Spain’s Innovative Medicines Platform Sets 2026 Strategy Focused on Clinical Research and Data Innovation

Consolidating leadership in clinical trials, using data for biomedical research, and the Biotechnology Law in Spain are the cornerstones of the innovative medicines platform’s strategy for 2026. This was announced Wednesday by the Coordinating Committee of the Spanish Technological Platform for Innovative Medicines.

This group, composed of nine representatives from public research centers and nine research managers from the pharmaceutical industry, has been working since 2005 to promote biomedical research through public-private partnerships.

Spain strengthens its leadership in clinical trials, biomedical data use, and biotechnology policy for 2026

It has also been announced that the major annual event promoted by the organization, the 19th Annual Conference of Biomedical Research Platforms, co-organized by Farmaindustria, Asebio, Nanomed, Fenin , and Veterindustria, will take place on May 28th in Barcelona.

The meeting also served to outline the 2026 strategy, which this year will focus on consolidating leadership in clinical research, with a particular emphasis on restoring Spanish and European competitiveness in a politically uncertain context where other global players are promoting innovation policies.

Likewise, the use of data for biomedical research, the consolidation and sustainability of European research projects, and the future Biotechnology Law are some of the key issues discussed at this meeting, which will help shape the agenda for the biomedical research platforms conference in Spain.

Farmaindustria has presented the 2026 Action Plan for the research pillar, which this year will revolve around 3 axes: in terms of preclinical research, the promotion of an ecosystem of excellence in preclinical research and open innovation; in clinical research, the consolidation of leadership; and in the secondary use of data and digitization, the positioning of Spain as a pioneer in the European Health Data Area (EHDA).

__

(Featured image by Faustina Okeke via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.